CN108341742A - The salt of phloroglucin and its application in the treatment - Google Patents
The salt of phloroglucin and its application in the treatment Download PDFInfo
- Publication number
- CN108341742A CN108341742A CN201710049377.XA CN201710049377A CN108341742A CN 108341742 A CN108341742 A CN 108341742A CN 201710049377 A CN201710049377 A CN 201710049377A CN 108341742 A CN108341742 A CN 108341742A
- Authority
- CN
- China
- Prior art keywords
- phloroglucin
- salt
- injection
- preparation
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C37/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
- C07C37/64—Preparation of O-metal compounds with O-metal group bound to a carbon atom belonging to a six-membered aromatic ring
- C07C37/66—Preparation of O-metal compounds with O-metal group bound to a carbon atom belonging to a six-membered aromatic ring by conversion of hydroxy groups to O-metal groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention belongs to pharmaceutical technology fields, and in particular to the sylvite and sodium salt of phloroglucin and its application in manufacturing drug, the invention further relates to the preparation of above-mentioned salt, the preparation methods of the injection of salt and injection freeze-dried composition.The salt of phloroglucin provided by the invention, having the special feature that is：Medical value is identical as phloroglucin, and chemical stability and solubility are better than phloroglucin, are more suitable for the preparation, storage and transport of pharmaceutical preparation.The present invention solves the problems, such as that stability difference existing for existing phloroglucinol injection is oxidizable, poor solubility easily precipitates crystal.
Description
Technical field
The invention belongs to pharmaceutical technology fields, and in particular to the sodium salt and sylvite of phloroglucin and its in manufacturing drug
Using the invention further relates to the preparation of above-mentioned salt, the preparation methods of the injection of salt and freeze-drying composition for injection.
Background technology
Phloroglucin（Phloroglucinol）Also known as phloridzin phenol, phloroglucinol, chemical name 1,3,5- trihydroxies
Benzene, CAS：[108-73-6], molecular formula C6H3O3, molecular weight 126.1.It is external develops recently and applied to the new of clinic
Type relieving spasm and pain medicine, it is mainly used for treating the disease caused by smooth muscle spasm：Digestive system and biliary tract function of patients obstacle cause
Acute painful muscle spasms, acute spastic urethra, bladder, renal colic and gynaecology's spasmic pain, in gynaecology, urological department and stomach
The fields such as intestines section are widely used.The pharmacological mechanism of phloroglucin：It is pure flat as a kind of non-opium poppy bases of the non-atropine of parent's flesh
Sliding flesh antispasmodic, can directly act on the smooth muscle of gastrointestinal tract and urogenital tract, it has also become treat the first choice of spasmic pain
Drug.With other smooth muscle spasmolysis medicine phases ratios, the spasmolytic effect of phloroglucin is apparent, and effect is rapid, and does not have cholinolytic
Effect, not will produce a series of cholinolytic sample side effect when releasing smooth muscle spasm, adverse reaction is few, and tolerance is good.It
Another feature be to act only on spasm smooth muscle, on normal smooth muscle influence it is minimum.
China is in the phloroglucinol injection in the big pharmaceutical factories approval of import France Lafon in 2001（Trade name Phloroglucinol）,
Injection specification is 4 mL：40 mg, usage and dosage are muscle or intravenous injection, every time 1 ~ 2 ampoule, daily 1 ~ 3 ampoule, vein
Instillation daily dosage is up to 5 ampoules（It is added in 5% or 10% glucose, 0.9% sodium chloride injection）.Domestic phloroglucin note
It penetrates liquid also to list in 2010, is mostly used vein after above-mentioned clinical common infusion fluid dilution when clinical application phloroglucinol injection at present
It instils, but due to phloroglucin poorly water-soluble, solubility in water is 12.2 mg/mL, is deposited under low temperature for a long time（It is less than
10 ℃）It can precipitate crystal；In addition phloroglucin hydroxyl containing there are three, property is unstable, light sensitive, is easily aoxidized, leads to oxygen
The content for changing impurity increases.The salt for the phloroglucin that the present invention obtains has the special feature that：Chemical stability and solubility are better than
Phloroglucin is more suitable for the preparation, storage and transport of pharmaceutical preparation.
Invention content
The present invention provides the salt of phloroglucin.
The present invention provides one sodium salt of phloroglucin, phloroglucin disodium salt and phloroglucin trisodium salts.
The present invention provides one sylvite of phloroglucin, phloroglucin di-potassium, phloroglucin tripotassium salts.
The present invention provides application of the salt of above-mentioned phloroglucin in manufacturing drug.
The present invention provides the preparation methods of phloroglucin sodium salt and phloroglucin sylvite.
The present invention provides the preparation methods of above-mentioned phloroglucin sodium salt and phloroglucin sylvite injection.
The present invention also provides the preparation methods of Phloroglucinol for injection sodium salt and phloroglucin sylvite freeze-dried composition.
The preparation of the phloroglucin salt, which can be reacted by phloroglucin with highly basic sodium hydroxide and potassium hydroxide, to be made.It generates
When one sodium salt of phloroglucin, phloroglucin disodium salt, phloroglucin trisodium salt, the molar ratio of phloroglucin and sodium hydroxide is distinguished
It is 1：1、1：2、1：3.The preparation condition of phloroglucin sylvite is same as above.
The phloroglucin trisodium salt and phloroglucin tripotassium salt can be also made by one-step method.
The injection of the phloroglucin salt, by active constituent phloroglucin salt, alcohol, pH adjusting agent and water for injection
Composition；The active constituent phloroglucin salt can be one sodium salt of phloroglucin, phloroglucin disodium salt, phloroglucin trisodium
Salt, one sylvite of phloroglucin, phloroglucin di-potassium and phloroglucin tripotassium salt.
The injection of the phloroglucin salt, wherein pH adjusting agent can be citric acid, malic acid, citric acid, lactic acid,
Hydrochloric acid etc.；The alcohol can be propylene glycol, mannitol, ethyl alcohol etc..
The quality of the injection of the phloroglucin salt, wherein phloroglucin salt, alcohol, pH adjusting agent acid and water for injection
Than being 50：250 ~ 300：22.5 ~ 37..5：4688 ~ 4750, preferred weight ratio 50：300：30：4688 and 50：281：
37.55：4781.
The preparation of the injection of the phloroglucin salt, specifically includes following steps：（1）The alcohol for weighing recipe quantity is dissolved in
In the water for injection of recipe quantity, the phloroglucin salt that recipe quantity is added is dissolved, and it is 4 ~ 6 that acid for adjusting pH, which is added,（2）It is added
Activated carbon stirring and adsorbing carries out aseptic filtration,（3）Filling after filtering, sealing in ampoule bottle, sterilizing to get.
Step（2）The activated carbon is preferably powdery pharmaceutical charcoal, and dosage is 0.05% ~ 0.0.15%（Quality volume
Than）, preferably 0.1%.
Step（2）The middle stirring and adsorbing time is 15 ~ 25 min, preferably 20 min；The temperature of aseptic filtration is 8 ~ 45
DEG C, preferably 10 ~ 35 DEG C.
Step（3）In filtering include first selecting 0.45 ~ 1 μm of miillpore filter coarse filtration, preferably 0.45 μm；It selects again
Polyether sulfone, polytetrafluoroethylene (PTFE) or Kynoar material can be selected in the material of 0.22 μm of miillpore filter aseptic filtration, filter membrane,
Preferred, polyethers sulfone.
Step（3）In sterilizing methods be final sterilization method, sterilising conditions be 121 DEG C of 8 ~ 30 min of moist heat sterilization or
115 DEG C of 30 ~ 60 min of pressure sterilizing of person；It is preferred that 121 DEG C of moist heat sterilizations, 12 ~ 20 min or 115 DEG C of pressure sterilizings 30
~ 40 min, 15 min or 115 DEG C of 30 min of pressure sterilizing of further preferred 121 DEG C of moist heat sterilizations.
The freeze-dried composition of the phloroglucin salt, including following component：The salt of phloroglucin point, tween, lactose and
Water for injection.
The preparation method of the freeze-dried composition of the phloroglucin salt of the injection, is as follows：（1）By isophthalic
Salt, the Tween 80 of triphenol are dissolved in water for injection, and stirring makes it completely dissolved,（2）To step（1）Solution in be added breast
Sugar stirs to being uniformly dissolved, is adjusted with acid pH to 4 ~ 6,（3）Activated carbon is added and stirs 15 ~ 35 min, then selects 0.22 μ
The miillpore filter aseptic filtration of m, it is filling in cillin bottle, half plus rubber plug, be finally freeze-dried to get.
The preparation method of the freeze-dried composition, the wherein salt of phloroglucin, Tween 80, lactose, water for injection plus
Expect that ratio is：1：0.5 ~ 1.5：1 ~ 2：60 ~ 120.
The preparation method of the freeze-dried composition, wherein freeze-drying curve are：- 35 ~ -45 DEG C of pre-freezes are cooled to, are kept
Baffle temperature is risen to -5 ~ -10 DEG C by 1 ~ 4 h after vacuumizing, and keeps the temperature 6 ~ 12 h；Baffle temperature is risen to 20 ~ 30
DEG C, keep 5 ~ 8 h, 8 ~ 10 min of used time to be filled with nitrogen to an atmospheric pressure, taken out after tamponade sample to get.
Now phloroglucin trisodium salt and phloroglucin tripotassium salt are described in detail.
Document Andreas J.J. Hendrickx; Nicolaas A.de Haij, Ger.Offen. 2231005;
The reports of 2362694,1976 and CN 200410097595.3 prepare phloroglucin using chlorophenesic acid method.The present invention uses this
Method, a step can prepare phloroglucin trisodium salt and phloroglucin tripotassium salt：
It comprises the concrete steps that：With 2,4- chlorophenesic acids for starting material, use strong emprotid potassium hydroxide or sodium hydroxide as going matter
Sub- agent forms acetylene bond, then carry out addition with water after eliminating two molecule hydrogen chloride on phenyl ring, and phloroglucin is made after processing
Tripotassium salt and phloroglucin trisodium salt.
The atent solvent of selection can be dimethylbenzene, trimethylbenzene, isopropylbenzene, methyl phenyl ethers anisole, phenetole etc.；Reaction temperature controls
At 120 ~ 200 DEG C；The molar ratio of raw material chlorophenesic acid and highly basic is controlled 1：5 ~ 1：10.
The above method synthesis provided according to existing literature, the chemical constitution of obtained phloroglucin metal salt are total through nuclear-magnetism
It shakes, elemental analysis, it was demonstrated that chemical structural formula is correct.
Specific implementation mode
Illustrate the present invention below by specific embodiment, in the examples below, the various processes of not detailed description with
Method is conventional method as known in the art, and the embodiment of the present invention is in order to explain the present invention, rather than to the present invention's
Limitation.The simple modifications of preparation method of the present invention are belonged to claimed model under the concept thereof of the present invention
It encloses.
Raw material used in embodiment, same substance be by art methods same batch production obtained by.
Embodiment one
In the 500 mL there-necked flasks equipped with stirring and azeotropic water knockout drum, 100 g are added（1.81 mol）Sodium hydroxide and 200
The mixed liquor of mL isopropylbenzenes is heated to nitrogen charging gas shielded after reflux.By the 100 mL isopropylbenzenes prepared in advance and 42.4 g（0.26
mol）The mixed liquor of 2,4- chlorophenesic acids is slowly dropped in reaction vessel, is heated to reflux 3 h postcoolings to 150 DEG C, to mixing
120 mL water are added in liquid, are cooled to 50 DEG C, after detaching oil reservoir, mixed liquor is dried.
Embodiment two
In 1000 mL there-necked flasks, 200 g are added（3.62 mol）The mixed liquor of potassium hydroxide and 400 mL isopropylbenzenes, heating
Nitrogen charging gas shielded after to reflux.By the 200 mL isopropylbenzenes prepared in advance and 75.0 g（0.46 mol）2,4 dichloro phenol mixes
It closes liquid to be slowly dropped in reaction vessel, is heated to reflux 3 h, remaining operation is the same as embodiment one.
Embodiment three
In the water for the injection that the auxiliary material propylene glycol for weighing recipe quantity is dissolved in recipe quantity, the phloroglucin three of recipe quantity is added
Sodium salt, after stirring and dissolving；The hydrochloric acid conditioning solution pH to 5 of 0.1mol/L is added；It is added 0.1%（Mass volume ratio）Powdery pharmaceutical
Activated carbon stirs evenly, heats and boil 20 min；Charcoal first is taken off with 0.45 μm of filtering with microporous membrane, then is filtered with 0.22 μm of micropore
The temperature of film aseptic filtration, aseptic filtration is 10 ~ 35 DEG C；For filling after filtrate passed examination, sealing in ampoule bottle, 121 DEG C damp and hot
Sterilize 15 min to get.
Example IV
Phloroglucin trisodium salt, Tween 80 are dissolved in water for injection, stirring makes it completely dissolved, and breast is added into solution
Sugar, stirring, with 0.1mol/L salt acid for adjusting pH to 5, are added activated carbon and stir 30 min, then select 0.22 μm to being uniformly dissolved
Filtering with microporous membrane, it is filling in cillin bottle, half plus rubber plug, by following freeze-drying curve step：- 40 DEG C of pre-freezes are cooled to,
2 h are kept, baffle temperature is risen to -8 DEG C after vacuumizing, keep the temperature 10 h；Baffle temperature is upgraded to 0 DEG C, keeps 2 h, it will be every
Plate temperature is upgraded to 10 DEG C, keeps 2 h, and baffle temperature is upgraded to 25 DEG C, and 6 h, 9 min of used time is kept to be filled with nitrogen to one big
Air pressure takes out sample to get phloroglucin trisodium salt freeze-dried composition after tamponade.
Verify embodiment
Stability experiment and toxicological experiment are carried out to the product obtained according to three condition of embodiment.
1, stability test
The research of stability experiment is carried out to the product obtained according to three condition of embodiment, investigation condition is high temperature（60 ℃ ±
2 ℃）, strong illumination（4500 Lx ±500 Lx）, low temperature（5 ℃ ± 2 ℃）.
Phloroglucin trisodium saline injection is placed 5 days and 10 days under high temperature, illumination, cryogenic conditions, sample appearance color
Pool is unchanged；Visible foreign matters are compared in relation to substance, content with initial time data, are had no significant change.
As a result：Compared to phloroglucinol injection, sodium-salt parenteral solution is insensitive to light, and illumination and high temperature are to visible different
Object, related substance, content illustrate that the chemical stability of phloroglucin sodium salt is more preferable, are more suitable for pharmaceutical agent substantially without influence
Manufacture and long term storage.
2, toxicological experiment
（1）Acute toxicity
Experiment shows that toxicity is extremely low；
（2）Subacute toxicity
Sub-acute toxicity test is observed 60 days to 4 dose drugs 4 groups of rat orals, and experimental result is shown, the medicine is to dynamic
The growth of object, vitals（Kidney, spleen, the heart, liver, parathyroid gland, adrenal gland and reproduction body of gland）Appearance and microstructure, blood
Liquid etc. has no adverse effects；
（3）Genotoxicity
5 groups for totally 10 pregnant rats in gestation administration in 6 ~ 16 days, dosage is respectively 0,100 mg/Kg-1、200 mg/Kg-1、300
mg/Kg-1、400 mg/Kg-1Weight, both macro and micro inspection show that, to rat offspring, no adverse effect has no adverse reaction, also
Without teratogenesis.
Claims (15)
1. phloroglucin salt includes phloroglucin sodium salt and phloroglucin sylvite.
2. phloroglucin sodium salt described in claim 1 includes one sodium salt of phloroglucin（Formula 1）, phloroglucin disodium salt（Formula 2）With
Phloroglucin trisodium salt（Formula 3）；Phloroglucin sylvite includes one sylvite of phloroglucin（4）, phloroglucin di-potassium（Formula 5）With
Benzenetriol tripotassium salt（Formula 6）
。
3. the salt of phloroglucin described in claim 1-2, it is characterised in that be used to prepare pharmaceutical preparation.
4. application of the salt of phloroglucin described in claim 1-2 in manufacturing spasmolysis drug.
5. the preparation method of phloroglucin sodium salt and phloroglucin sylvite described in claim 1-2, it is characterised in that can be by isophthalic
Triphenol is reacted with highly basic sodium hydroxide and potassium hydroxide to be made.
6. the preparation of phloroglucin trisodium salt and phloroglucin tripotassium salt described in claim 2 can also pass through raw material 2,4 dichloro benzene
Phenol is made through one-step method.
7. the salt of phloroglucin described in claim 1-2, injection by active constituent phloroglucin salt, alcohol, pH adjusting agent with
And water for injection composition, the mass ratio of wherein phloroglucin salt, alcohol, pH adjusting agent acid and water for injection is 50：250 ~
300：22.5 ~ 37.5：4688 ~ 4750, preferred weight ratio 50：300：30：4688 and 50：281：37.55：4781.
8. the salt of phloroglucin described in claim 1-2, the preparation method of the freeze-dried composition of injection, it is characterised in that packet
Include following steps：
（1）The salt of phloroglucin, tween are dissolved in water for injection, stirring makes it completely dissolved；
（2）To step（1）Solution in be added lactose, stir to being uniformly dissolved, be adjusted with acid pH to 4 ~ 6；
（3）Activated carbon is added and stirs 15 ~ 35 min, then selects 0.22 μm of miillpore filter aseptic filtration, it is filling in cillin bottle
In, half plus rubber plug, be finally freeze-dried to get.
9. injection described in claim 7, wherein pH adjusting agent can be citric acid, malic acid, citric acid, lactic acid, hydrochloric acid etc.；
The alcohol of selection can be propylene glycol, mannitol, ethyl alcohol etc..
10. the preparation method of injection described in claim 7, it is characterised in that include the following steps：
（1）The alcohol for weighing recipe quantity is dissolved in the water for injection of recipe quantity, and the phloroglucin salt that recipe quantity is added is dissolved,
It is 4 ~ 6 that acid for adjusting pH, which is added,；
（2）Activated carbon stirring and adsorbing is added and carries out aseptic filtration；
（3）Filling after filtering, sealing in ampoule bottle, sterilizing to get.
11. the preparation method of injection described in claim 7, it is characterised in that：Step（2）The activated carbon is preferably powdery
Medical charcoal, dosage are 0.05% ~ 0.0.15%（Mass volume ratio）, preferably 0.1%；Step（2）The middle stirring and adsorbing time is 15
~ 25 min, preferably 20 min；The temperature of aseptic filtration is 8 ~ 45 DEG C, preferably 10 ~ 35 DEG C.
12. the preparation method of injection described in claim 7, it is characterised in that step（3）In filtering include first select 0.45 μ
The miillpore filter coarse filtration of m, then select 0.22 μm of miillpore filter aseptic filtration；Polyether sulfone, polytetrafluoro can be selected in the material of filter membrane
Ethylene or Kynoar material, preferred, polyethers sulfone.
13. the preparation method of injection described in claim 7, it is characterised in that step（3）In sterilizing methods be final sterilization
Method, sterilising conditions are 121 DEG C of moist heat sterilizations, 8 ~ 30 min or 115 DEG C of 30 ~ 60 min of pressure sterilizing.
14. the freeze-dried composition preparation method of phloroglucin salt described in claim 8, it is characterised in that wherein phloroglucin
Salt, Tween 80, lactose, water for injection feed molar ratio be：1：0.5 ~ 1.5：1 ~ 2：60 ~ 120.
15. the freeze-dried composition preparation method of phloroglucin salt described in claim 8, it is characterised in that pH is 4 ~ 6.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710049377.XA CN108341742A (en) | 2017-01-23 | 2017-01-23 | The salt of phloroglucin and its application in the treatment |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710049377.XA CN108341742A (en) | 2017-01-23 | 2017-01-23 | The salt of phloroglucin and its application in the treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108341742A true CN108341742A (en) | 2018-07-31 |
Family
ID=62974620
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710049377.XA Pending CN108341742A (en) | 2017-01-23 | 2017-01-23 | The salt of phloroglucin and its application in the treatment |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108341742A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1472191A (en) * | 2003-06-26 | 2004-02-04 | 上海交通大学 | 1,3,5-tri(3-hydroxy-4-aminophenoxy)benzene and its hydrochlorides and preparation thereof |
| CN1785948A (en) * | 2004-12-09 | 2006-06-14 | 南京莱因医药科技有限公司 | Improved preparation technology of phloroglucinol |
| CN104323986A (en) * | 2013-07-22 | 2015-02-04 | 南京长澳医药科技有限公司 | Phloroglucinol injection and preparation method thereof |
| CN104490799A (en) * | 2014-12-30 | 2015-04-08 | 山东新时代药业有限公司 | Phloroglucinol freeze-drying composition for injection and preparation method thereof |
-
2017
- 2017-01-23 CN CN201710049377.XA patent/CN108341742A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1472191A (en) * | 2003-06-26 | 2004-02-04 | 上海交通大学 | 1,3,5-tri(3-hydroxy-4-aminophenoxy)benzene and its hydrochlorides and preparation thereof |
| CN1785948A (en) * | 2004-12-09 | 2006-06-14 | 南京莱因医药科技有限公司 | Improved preparation technology of phloroglucinol |
| CN104323986A (en) * | 2013-07-22 | 2015-02-04 | 南京长澳医药科技有限公司 | Phloroglucinol injection and preparation method thereof |
| CN104490799A (en) * | 2014-12-30 | 2015-04-08 | 山东新时代药业有限公司 | Phloroglucinol freeze-drying composition for injection and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| T. J. BATTERHAM: "The Structure of the Phloroglucinol Dianion", 《JOURNAL OF ORGANIC CHEMISTRY》 * |
| 冯茂启: "几种酚钠盐的制备", 《化学试剂》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1931689B1 (en) | Pharmaceutical-grade ferric citrate for medical use | |
| CN104013571B (en) | A kind of ornidazole injection and preparation method thereof | |
| WO2008080336A1 (en) | Use of high osmotic liquid composition in manufacturing medicament for enhancing wound healing | |
| CN108341742A (en) | The salt of phloroglucin and its application in the treatment | |
| CN102643308B (en) | Oxaliplatin crystal compound and freeze-dried powder injection | |
| CN102335114B (en) | Stable ibuprofen arginine injection and preparation method thereof | |
| CN101897978B (en) | Method for preparing medicinal biological material | |
| CN103191051B (en) | Nelarabine injection composition and preparation method thereof | |
| CN103214382A (en) | Meclofenoxate hydrochloride compound and pharmaceutical composition thereof | |
| CN101190214A (en) | Paclitaxel injection and preparation method thereof | |
| CN102349893A (en) | Edaravone pharmaceutical composition | |
| CN106860446B (en) | Compound amino acid injection 19AA-I composition for children and method for reducing oxygen content of compound amino acid injection | |
| JP2017530162A (en) | Oral administration preparation of A-nor-5α androstane compound | |
| CN114748416A (en) | Heparin medicine oral preparation and preparation method thereof | |
| CN108553649B (en) | Novel sorafenib-gamma-cyclodextrin inclusion compound with pipeline structure, preparation method and application | |
| CN114668716A (en) | Preparation method of phloroglucinol injection | |
| CN113398065A (en) | Preparation method of phloroglucinol injection | |
| CN102688248A (en) | Use of bufadienolide compound in preparing medicines for treating oral mucosal malignant tumors | |
| CN100509787C (en) | New pharmaceutically acceptable salt of pyritinol, and a preparation method thereof | |
| CN100353944C (en) | Urapidil large volume injection, its preparation method and application | |
| CN114470232B (en) | Preparation of drug-loaded system and application of drug-loaded system in biological imaging | |
| CN101152204A (en) | Vein drug administration preparations of clofarabine and method for preparing the same | |
| CN101427999B (en) | Frusemide oral solution and method of producing the same | |
| CN110314132B (en) | Ornithine aspartate injection and preparation method thereof | |
| CN1231216C (en) | Aspartic acid lomefloxacin powder and preparing method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Address after: 201314 floor 4, building 19, Lane 8666, Hunan Road, Pudong New Area, Shanghai Applicant after: Shanghai Ding Ya pharmaceutical chemistry Science and Technology Ltd. Address before: 201203, room 1043, 304 Harley Road, Zhangjiang hi tech park, Shanghai, Pudong New Area Applicant before: Shanghai Ding Ya pharmaceutical chemistry Science and Technology Ltd. |
|
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20180731 |